• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

Amir T. Fathi, MD


  • Brunner AM, Blonquist TM, Sadrzadeh H, Perry AM, Attar EC, Amrein PC, Ballen KK, Chen YB, Neuberg DS, Fathi AT.Population-based disparities in survival among patients with core-binding factor acute myeloid leukemia: A SEER database analysis.Leuk Res. 2014 Jul;38(7):773-80.
  • Wander SA, Levis MJ, Fathi AT.The evolving role of FLT3 inhibitors in acute myeloid leukemia: quizartinib and beyond.Ther Adv Hematol. 2014 Jun;5(3):65-77.
  • Graubert TA, Brunner AM, Fathi AT.New Molecular Abnormalities and Clonal Architecture in AML: From Reciprocal Translocations to Whole-Genome Sequencing.Am Soc Clin Oncol Educ Book. 2014;34:e334-40.
  • Emadi A, Jun SA, Tsukamoto T, Fathi AT, Minden MD, Dang CV.Inhibition of glutaminase selectively suppresses the growth of primary acute myeloid leukemia cells with IDH mutations.Exp Hematol. 2014 Apr;42(4):247-51.
  • Fathi AT, Sadrzadeh H, Comander AH, Higgins MJ, Bardia A, Perry A, Burke M, Silver R, Matulis CR, Straley KS, Yen KE, Agresta S, Kim H, Schenkein DP, Borger DR.Isocitrate Dehydrogenase 1 (IDH1) Mutation in Breast Adenocarcinoma Is Associated With Elevated Levels of Serum and Urine 2-Hydroxyglutarate.Oncologist. 2014 Apr 23.
  • Fathi AT, Chen YB.Treatment of Relapse of Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation.Curr Hematol Malig Rep. 2014 Mar 19.
  • Akbay EA, Moslehi J, Christensen CL, Saha S, Tchaicha JH, Ramkissoon SH, Stewart KM, Carretero J, Kikuchi E, Zhang H, Cohoon TJ, Murray S, Liu W, Uno K, Fisch S, Jones K, Gurumurthy S, Gliser C, Choe S, Keenan M, Son J, Stanley I, Losman JA, Padera R, Bronson RT, Asara JM, Abdel-Wahab O, Amrein PC, Fathi AT, Danial NN, Kimmelman AC, Kung AL, Ligon KL, Yen KE, Kaelin WG, Bardeesy N, Wong KK.D-2-hydroxyglutarate produced by mutant IDH2 causes cardiomyopathy and neurodegeneration in mice.Genes Dev. 2014 Mar 1;28(5):479-90.
  • Fathi AT, Dec GW, Richter JM, Chen YB, Schwartzenberg SS, Holmvang G, Hasserjian RP.Case records of the Massachusetts General Hospital. Case 7-2014. A 27-year-old man with diarrhea, fatigue, and eosinophilia.N Engl J Med. 2014 Feb 27;370(9):861-72.
  • Fathi AT, Chen YB.CD30: a new target for ALL?.Leuk Lymphoma. 2014 Mar;55(3):478-9.
  • Fathi AT.Emergence of crenolanib for FLT3-mutant AML.Blood. 2013 Nov 21;122(22):3547-8.
  • O'Brien S, Radich JP, Abboud CN, Akhtari M, Altman JK, Berman E, DeAngelo DJ, Deininger M, Devine S, Fathi AT, Gotlib J, Jagasia M, Kropf P, Moore JO, Pallera A, Pinilla-Ibarz J, Reddy VV, Shah NP, Smith BD, Snyder DS, Wetzler M, Gregory K, Sundar H.Chronic Myelogenous Leukemia, Version 1.2014.J Natl Compr Canc Netw. 2013 Nov;11(11):1327-40.
  • Peloquin GL, Chen YB, Fathi AT.The evolving landscape in the therapy of acute myeloid leukemia.Protein Cell. 2013 Oct;4(10):735-46.
  • Attar EC, Amrein PC, Fraser JW, Fathi AT, McAfee S, Wadleigh M, Deangelo DJ, Steensma DP, Stone RM, Foster J, Neuberg D, Ballen KK.Phase I dose escalation study of bortezomib in combination with lenalidomide in patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML).Leuk Res. 2013 Sep;37(9):1016-20.
  • Fathi AT, Le L, Hasserjian RP, Sadrzadeh H, Levis M, Chen YB.FLT3 inhibitor-induced neutrophilic dermatosis.Blood. 2013 Jul 11;122(2):239-42.
  • Zhang Y, Wang J, Wheat J, Chen X, Jin S, Sadrzadeh H, Fathi AT, Peterson RT, Kung AL, Sweetser DA, Yeh JR.AML1-ETO mediates hematopoietic self-renewal and leukemogenesis through a COX/β-catenin signaling pathway.Blood. 2013 Jun 13;121(24):4906-16.
  • Sadrzadeh H, Kerr DA, Cin PD, Lindeman NI, Hasserjian RP, Fathi AT.A unique PML-RARα rearrangement involving chromosomes 11, 15, and 17 in a patient with acute promyelocytic leukemia.Exp Hematol. 2013 May 6.
  • Brunner AM, Campigotto F, Sadrzadeh H, Drapkin BJ, Chen YB, Neuberg DS, Fathi AT.Trends in all-cause mortality among patients with chronic myeloid leukemia: A Surveillance, Epidemiology, and End Results database analysis.Cancer. 2013 Apr 26.
  • Brunner AM, Sadrzadeh H, Feng Y, Drapkin BJ, Ballen KK, Attar EC, Amrein PC, McAfee SL, Chen YB, Scd DS, Fathi AT.Association between baseline body mass index (BMI) and overall survival among patients over age 60 with acute myeloid leukemia (AML).Am J Hematol. 2013 Apr 26.
  • Sadrzadeh H, Hasserjian R, Fathi AT.Pure erythroid leukemia evolving from a therapy-related myelodysplastic syndrome secondary to treatment for chronic lymphocytic leukemia.Am J Hematol. 2013 Mar;88(3):240-1.
  • Sadrzadeh H, Huck AE, Chen YB, Hasserjian RP, Fathi AT.Philadelphia chromosome positive B-cell lymphoblastic lymphoma isolated to bone.Leuk Lymphoma. 2013 Jan 30.
  • Courville EL, Wu Y, Kourda J, Roth CG, Brockmann J, Muzikansky A, Fathi AT, de Leval L, Orazi A, Hasserjian RP.Clinicopathologic analysis of acute myeloid leukemia arising from chronic myelomonocytic leukemia.Mod Pathol. 2013 Jan 11.
  • Sadrzadeh H, Abtahi SM, Fathi AT.Infectious pathogens and hematologic malignancy.Discov Med. 2012 Dec;14(79):421-33.
  • Fathi AT, Sadrzadeh H, Borger DR, Ballen KK, Amrein PC, Attar EC, Foster J, Burke M, Lopez HU, Matulis CR, Edmonds KM, Iafrate AJ, Straley KS, Yen KE, Agresta S, Schenkein DP, Hill C, Emadi A, Neuberg DS, Stone RM, Chen YB.Prospective serial evaluation of 2-hydroxyglutarate, during treatment of newly diagnosed acute myeloid leukemia, to assess disease activity and therapeutic response.Blood. 2012 Oct 16.
  • Fathi AT, Preffer FI, Sadrzadeh H, Ballen KK, Amrein PC, Attar EC, McAfee SL, Dillon L, Chen YB, Hasserjian RP.CD30 expression in acute myeloid leukemia is associated with FLT3-internal tandem duplication mutation and leukocytosis.Leuk Lymphoma. 2012 Sep 28.
  • Fathi AT, Chen YB, Carter BW, Ryan RJ.Case records of the Massachusetts General Hospital. Case 24-2012. A 38-year-old man with abdominal pain and altered mental status.N Engl J Med. 2012 Aug 9;367(6):552-63.
  • Fathi A, Levis M.FLT3 inhibitors: a story of the old and the new.Curr Opin Hematol. 2011 Mar;18(2):71-6.
  • Fathi AT, Grant S, Karp JE.Exploiting cellular pathways to develop new treatment strategies for AML.Cancer Treat Rev. 2010 Apr;36(2):142-50. Review.
  • Fathi AT, Karp JE.New agents in acute myeloid leukemia: beyond cytarabine and anthracyclines.Curr Oncol Rep. 2009 Sep;11(5):346-52. Review.